Stumping for stem cells

The linkurl:California stem cell policy and advocacy juggernaut;http://www.the-scientist.com/news/display/23097/ was in full steam this weekend at Stanford University. The two-day linkurl:Stem Cell Policy and Advocacy Summit II: Empowering the Pro-Cures Coalition;http://www.pro-cures.com offered a banquet of the usual servings, including scientific updates, discussions of linkurl:ethics;http://www.the-scientist.com/blog/display/23251/ and legal issues, and how-to primers on grassroots advocacy.

By | June 14, 2006

The linkurl:California stem cell policy and advocacy juggernaut;http://www.the-scientist.com/news/display/23097/ was in full steam this weekend at Stanford University. The two-day linkurl:Stem Cell Policy and Advocacy Summit II: Empowering the Pro-Cures Coalition;http://www.pro-cures.com offered a banquet of the usual servings, including scientific updates, discussions of linkurl:ethics;http://www.the-scientist.com/blog/display/23251/ and legal issues, and how-to primers on grassroots advocacy. There was some different fare, however: -- A variety of nationwide polls (e.g., linkurl:Center for the Advancement of Medical Research;http://www.camradvocacy.org/camr_news.aspx?rid=051606B and linkurl:The Genetics and Public Policy Institute;http://www.dnapolicy.org/pub.reports.php?action=detail&report_id=1)have reported that the public supports somatic cell nuclear transfer by approximately 65-70%. That should be good news, but instead Governor Jim Doyle (Wis.) and others said this is evidence of the focus, organization and powerful voice of the 25% opposing it, and should be a rallying cry for supporters. Proposals to counter this force included opening up laboratories for visitation by the public on a monthly or quarterly basis to educate the public on their research. -- The public's lack of understanding of the science behind the research was highlighted during a talk by Stephen Levick, professor of psychiatry at the University of Pennsylvania School of Medicine, on Sunday when he noted that Irv Weissman had recently asked several people to draw a picture of a blastocyst; each of the respondents drew a fetus. -- Bob Klein, chairman of the California Institute of Regenerative Medicine and a major force behind California's Prop. 71, claimed that even minor overall savings that are foreseen to arise from human embryonic stem cell research applied to linkurl:better treatments for chronic diseases;http://www.the-scientist.com/blog/display/23262/ could save significant amounts of money within the US health care system. By his calculations, a 2% cost savings in 6 out of 70 conditions thought to be good targets for therapies from the research would result in a 200% payback on California's Proposition 71 investment. For context, Klein pointed out that $100 billion was saved in the costs of housing of polio victims after Jonas Salk developed the polio vaccine in 1952 and after the first successful big trial of the vaccine in 1955.
Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Mettler Toledo
Mettler Toledo
Life Technologies